Preprint Review Version 1 This version is not peer-reviewed

ASSURED-SQVM Diagnostics for COVID-19: Addressing the Why, When, Where, Who, What and How of Testing

Version 1 : Received: 27 May 2020 / Approved: 31 May 2020 / Online: 31 May 2020 (16:35:25 CEST)

How to cite: Kumar, M.; Iyer, S.S. ASSURED-SQVM Diagnostics for COVID-19: Addressing the Why, When, Where, Who, What and How of Testing. Preprints 2020, 2020050481 (doi: 10.20944/preprints202005.0481.v1). Kumar, M.; Iyer, S.S. ASSURED-SQVM Diagnostics for COVID-19: Addressing the Why, When, Where, Who, What and How of Testing. Preprints 2020, 2020050481 (doi: 10.20944/preprints202005.0481.v1).

Abstract

COVID-19, the disease caused by the new coronavirus, SARS-CoV-2, has caused significant human and economic burden. Of the three major methods to mitigate the effect of the virus, diagnostics have become the focal point because vaccines and therapeutics, despite the intense effort of scientists worldwide, will take months to develop, test for safety and efficacy, scaleup and distribute to millions. This perspective aims to clarify some of the issues related to COVID-19 diagnostics and highlights some of the challenges key stakeholders including policymakers, businesses, managers, scientists and individuals face during this evolving pandemic.

Subject Areas

COVID-19; SARS-CoV-2; diagnostics; point of care

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.